Ignite Creation Date:
2025-12-26 @ 11:45 AM
Ignite Modification Date:
2025-12-31 @ 11:32 AM
Study NCT ID:
NCT00495716
Status:
TERMINATED
Last Update Posted:
2023-03-07
First Post:
2007-06-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006558', 'term': 'Herpes Genitalis'}], 'ancestors': [{'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D006561', 'term': 'Herpes Simplex'}, {'id': 'D006566', 'term': 'Herpesviridae Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000212', 'term': 'Acyclovir'}], 'ancestors': [{'id': 'D006147', 'term': 'Guanine'}, {'id': 'D007042', 'term': 'Hypoxanthines'}, {'id': 'D011688', 'term': 'Purinones'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'vrc@uw.edu', 'phone': '206-520-4340', 'title': 'Clinic Director', 'organization': 'University of Washington Virology Research Clinic'}, 'certainAgreement': {'piSponsorEmployee': True}, 'limitationsAndCaveats': {'description': 'Study terminated; investigator relocated and study funding ended. Results cannot be analyzed because data were not collected.'}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Episodic Treatment Arm', 'description': '800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence\n\nacyclovir: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence', 'otherNumAtRisk': 35, 'otherNumAffected': 0, 'seriousNumAtRisk': 35, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Suppressive Therapy Arm', 'description': '400 mg acyclovir orally twice daily for 1 year\n\nacyclovir: 400 mg acyclovir orally twice daily for 1 year', 'otherNumAtRisk': 37, 'otherNumAffected': 0, 'seriousNumAtRisk': 37, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'The Effect of Suppressive Antiviral Therapy on Sexual Behavior Among HSV-2 Seropositive Persons With Multiple Sexual Partners.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Episodic Treatment Arm', 'description': '800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence\n\nacyclovir: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence'}, {'id': 'OG001', 'title': 'Suppressive Therapy Arm', 'description': '400 mg acyclovir orally twice daily for 1 year\n\nacyclovir: 400 mg acyclovir orally twice daily for 1 year'}], 'timeFrame': '1 year', 'reportingStatus': 'POSTED', 'populationDescription': 'Study terminated; investigator relocated and study funding ended. Results cannot be analyzed because data were not collected.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Episodic Treatment Arm', 'description': '800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence\n\nacyclovir: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence'}, {'id': 'FG001', 'title': 'Suppressive Therapy Arm', 'description': '400 mg acyclovir orally twice daily for 1 year\n\nacyclovir: 400 mg acyclovir orally twice daily for 1 year'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '35'}, {'groupId': 'FG001', 'numSubjects': '37'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}, {'groupId': 'FG001', 'numSubjects': '24'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '13'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'BG000'}, {'value': '37', 'groupId': 'BG001'}, {'value': '72', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Episodic Treatment Arm', 'description': '800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence\n\nacyclovir: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence'}, {'id': 'BG001', 'title': 'Suppressive Therapy Arm', 'description': '400 mg acyclovir orally twice daily for 1 year\n\nacyclovir: 400 mg acyclovir orally twice daily for 1 year'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '40', 'groupId': 'BG000', 'lowerLimit': '18', 'upperLimit': '79'}, {'value': '39', 'groupId': 'BG001', 'lowerLimit': '22', 'upperLimit': '63'}, {'value': '39', 'groupId': 'BG002', 'lowerLimit': '18', 'upperLimit': '79'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '29', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '22', 'groupId': 'BG001'}, {'value': '43', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '24', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '25', 'groupId': 'BG001'}, {'value': '46', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 72}}, 'statusModule': {'whyStopped': 'Investigator relocated and study funding ended.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2008-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-02', 'completionDateStruct': {'date': '2010-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-02-13', 'studyFirstSubmitDate': '2007-06-29', 'resultsFirstSubmitDate': '2018-03-15', 'studyFirstSubmitQcDate': '2007-07-02', 'lastUpdatePostDateStruct': {'date': '2023-03-07', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-01-16', 'studyFirstPostDateStruct': {'date': '2007-07-03', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2020-01-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2010-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The Effect of Suppressive Antiviral Therapy on Sexual Behavior Among HSV-2 Seropositive Persons With Multiple Sexual Partners.', 'timeFrame': '1 year'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Genital Herpes']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners.\n\nStudy terminated; investigator relocated and study funding ended. Results were never analyzed because data were not collected.', 'detailedDescription': 'We plan to conduct a randomized controlled trial of chronic suppressive acyclovir, 400 mg orally twice daily (standard dose) versus episodic acyclovir for treatment of genital herpes recurrences. We will enroll 500 HSV-2 seropositive single persons (250 per arm), stratified by gender and history of symptomatic genital herpes, and prospectively follow them for 1 year to assess sexual behavior, adherence to therapy, and herpes-related quality of life. These outcomes will be measured by self-report in a confidential, computer-based assessment. We plan to use data from this trial to model the effect that increasing the proportion of sexually-active HSV-2 infected persons taking suppressive therapy will have on population-level incidence and prevalence of HSV-2.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age 18 years or older\n* HSV-2 seropositive by Western blot OR documented culture positive for HSV-2 from anogenital site\n* 2 or more vaginal or anal sex partners in the past 12 months\n* Not currently in a monogamous sexual relationship of \\>= 6 months duration\n* Willing and able to be randomized and comply with the study protocol\n\nExclusion Criteria:\n\n* Pregnancy or intention to become pregnant within the next year\n* Suppressive therapy with acyclovir, valacyclovir, or famciclovir within 2 weeks of enrollment/randomization\n* 6 or more symptomatic herpes recurrences in the prior 12 months or in the 12 months prior to starting suppressive therapy if on suppressive therapy during the prior 12 months\n* HIV seropositive or known immunocompromising medical condition. HIV negative test must be performed within 60 days of Visit 1 (enrollment/randomization). For current or former participants in HIV vaccine clinical trials for whom HIV vaccine-induced seropositivity potentially leading to vaccine study unblinding may be a concern, a report from the Seattle HVTU documenting that the participant is HIV uninfected based on HIV testing done within 60 days of Visit 1 will be accepted in lieu of HIV testing done at our clinic.\n* Intention to move from the Seattle area within the next year\n* Known allergy, intolerance, or medical contraindication to acyclovir\n* Inability to understand, speak, and read English'}, 'identificationModule': {'nctId': 'NCT00495716', 'briefTitle': 'Effect of HSV-2 Suppressive Therapy on Sexual Behavior', 'organization': {'class': 'OTHER', 'fullName': 'University of Washington'}, 'officialTitle': 'Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission', 'orgStudyIdInfo': {'id': '32545'}, 'secondaryIdInfos': [{'id': 'K23AI071257-01A1', 'link': 'https://reporter.nih.gov/quickSearch/K23AI071257-01A1', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Episodic Treatment Arm', 'description': '800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence', 'interventionNames': ['Drug: acyclovir']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Suppressive Therapy Arm', 'description': '400 mg acyclovir orally twice daily for 1 year', 'interventionNames': ['Drug: acyclovir']}], 'interventions': [{'name': 'acyclovir', 'type': 'DRUG', 'description': '800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence', 'armGroupLabels': ['Episodic Treatment Arm']}, {'name': 'acyclovir', 'type': 'DRUG', 'description': '400 mg acyclovir orally twice daily for 1 year', 'armGroupLabels': ['Suppressive Therapy Arm']}]}, 'contactsLocationsModule': {'locations': [{'zip': '98104', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'University of Washington Virology Research Clinic', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}], 'overallOfficials': [{'name': 'Anna Wald, MD, MPH', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Washington'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Washington', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'class': 'NIH'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Anna Wald', 'investigatorAffiliation': 'University of Washington'}}}}